Latest filing published 10 Sept 2026 for Recursion Pharmaceuticals, INC., €68k. Read the official filing
Najat Khan appears in our data through filings on Recursion Pharmaceuticals, Inc. shares, published by SEC (Form 4). We count 12 filings; the first trade dates from 1 August 2024 and the latest from 8 September 2026.
No open-market purchase appears, only 3 sales worth €618k. Other entries cover 9 share grants. So far in 2026, the count stands at no purchases and 2 sales.
The newest entry dates from 10 September 2026: an open-market sale of €68k, in Recursion Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations